Goldman Sachs on Revolution (RVMD): 'Catalyst-rich 2026 underpins the breadth of the clinical portfolio'
Tweet Send to a Friend
Goldman Sachs analyst Andrea Newkirk reiterated a Buy rating and $73.00 price target on Revolution (NASDAQ: RVMD).The analyst comments "In ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
